Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

264 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High-Grade Progression Confers Poor Survival in Pancreatic Neuroendocrine Tumors.
Botling J, Lamarca A, Bajic D, Norlén O, Lönngren V, Kjaer J, Eriksson B, Welin S, Hellman P, Rindi G, Skogseid B, Crona J. Botling J, et al. Among authors: lamarca a. Neuroendocrinology. 2020;110(11-12):891-898. doi: 10.1159/000504392. Epub 2019 Oct 29. Neuroendocrinology. 2020. PMID: 31658459
Pancreatic biomarkers: could they be the answer?
Lamarca A, Feliu J. Lamarca A, et al. World J Gastroenterol. 2014 Jun 28;20(24):7819-29. doi: 10.3748/wjg.v20.i24.7819. World J Gastroenterol. 2014. PMID: 24976720 Free PMC article. Review.
Ki-67 index and response to chemotherapy in patients with neuroendocrine tumours.
Childs A, Kirkwood A, Edeline J, Luong TV, Watkins J, Lamarca A, Alrifai D, Nsiah-Sarbeng P, Gillmore R, Mayer A, Thirlwell C, Sarker D, Valle JW, Meyer T. Childs A, et al. Among authors: lamarca a. Endocr Relat Cancer. 2016 Jul;23(7):563-70. doi: 10.1530/ERC-16-0099. Endocr Relat Cancer. 2016. PMID: 27412968
Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response.
Lamarca A, Barriuso J, Kulke M, Borbath I, Lenz HJ, Raoul JL, Meropol NJ, Lombard-Bohas C, Posey J, Faivre S, Raymond E, Valle JW. Lamarca A, et al. Br J Cancer. 2018 Jan;118(2):181-188. doi: 10.1038/bjc.2017.402. Epub 2017 Nov 21. Br J Cancer. 2018. PMID: 29161241 Free PMC article.
264 results